Ebglyss is a new biologic treatment for moderate-to-severe eczema that isn’t controlled with topical therapies. The ...

The Food and Drug Administration had recently approved a new drug for the treatment of atopic dermatitis (eczema), which can ...

Trachomatous trichiasis, a potentially blinding condition where inward-turned eyelashes scratch the front of the eye, can successfully be treated by either of the two most common types of eyelid ...

The FDA has approved Ebglyss (lebrikizumab-lbkz), a new biologic treatment for moderate-to-severe atopic dermatitis in people ...

EBGLYSS is an FDA-approved drug for treating moderate-to-severe eczema by targeting IL-13, offering relief to patients ...

Shingles is “one of the worst pains in medicine.” A vaccine is highly effective at preventing it, but many people don’t get ...

The US Food and Drug Administration (FDA) has approved the targeted interleukin (IL)-13 inhibitor lebrikizumab (Ebglyss) for ...

In some, it can happen in and around the eyes, eyelids ... and cancer or treatments like radiation or medications to prevent the rejection of transplanted organs—all of which lower immunity and ...

The FDA approved lebrikizumab (Ebglyss) for treating atopic dermatitis in adults and children ages 12 years and up, drugmaker ...

Lilly has exclusive rights for development and commercialization of EBGLYSS in the U.S. and the rest of the world outside Europe. Lilly's partner Almirall S.A. has licensed the rights to develop and ...

The study, funded by the National Institutes of Health, supports no change to surgical technique for trichiasis management.

The US food and Drug Administration has approved lebrikizumab for treatment of atopic dermatitis in adults and children ages ...